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Adherence to tuberculosis (TB) treatment and antiretroviral therapy (ART) reduces morbid-
ity and mortality among persons co-infected with TB/HIV. We measured adherence and
determined factors associated with non-adherence to concurrent TB treatment and ART
among co-infected persons in two provinces in South Africa.
Methods
A convenience sample of 35 clinics providing integrated TB/HIV care was included due to
financial and logistic considerations. Retrospective chart reviews were conducted among
persons who received concurrent TB treatment and ART and who had a TB treatment out-
come recorded during 1 January 2008–31 December 2010. Adherence to concurrent TB
and HIV treatment was defined as: (1) taking80% of TB prescribed doses by directly
observed therapy (DOT) as noted in the patient card; and (2) taking >90% ART doses as
documented in the ART medical record during the concurrent treatment period (period of
time when the patient was prescribed both TB treatment and ART). Risk ratios (RRs) and
95% confidence intervals (CIs) were used to identify factors associated with non-
adherence.
Results
Of the 1,252 persons receiving concurrent treatment, 138 (11.0%) were not adherent. Non-
adherent persons were more likely to have extrapulmonary TB (RR: 1.71, 95% CI: 1.12 to
2.60) and had not disclosed their HIV status (RR: 1.96, 95% CI: 1.96 to 3.76).
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Conclusions
The majority of persons with TB/HIV were adherent to concurrent treatment. Close monitor-
ing and support of persons with extrapulmonary TB and for persons who have not disclosed
their HIV status may further improve adherence to concurrent TB and antiretroviral
treatment.
Introduction
South Africa remains at the center of the HIV and tuberculosis epidemics [1]. Among high TB
burden countries, South Africa had an incidence rate of 509 new cases co-infected with TB and
HIV (TB/HIV) per 100,000 persons in 2014, leading to a substantial number with TB/HIV
who require concurrent treatment for both diseases [2].
Prior to 2009, South African guidelines reserved initiation of antiretroviral therapy (ART)
for adults with CD4 counts< 200/mm3 [3]. In 2010, revised guidelines outlined eligibility for
ART among persons with TB/HIV to include those with CD4 cell count 350 cells/mm3
and those with multidrug-resistant or extensively drug-resistant TB (MDR-TB or XDR-TB),
irrespective of CD4 cell count [4]. The World Health Organization (WHO) published recom-
mendations in the same year promoting the initiation of ART for all persons with HIV/TB
co-infection, irrespective of the CD4 cell count [5].
Adherence to both TB treatment and ART is a key determinant of TB/HIV treatment out-
comes, including lower morbidity and mortality [6–7], and essential to minimize the emer-
gence of both TB and ART drug resistance [8]. Previous studies have identified HIV beliefs,
stigma associated with HIV disclosure, food and transportation costs, substance use, pill bur-
den, adverse drug events, and poor communication with healthcare workers (HCWs) as factors
associated with ART non-adherence [9–10]. Similar factors have been cited as increasing risk
for non-adherence to tuberculosis treatment [11–12]. A South African study reported that
patient perception of poor attitudes among HCWs and the patient changing residence during
TB treatment were both independently associated with TB treatment interruption among both
new and re-treatment patients [11]. A qualitative study in Brazil, another high burden country,
found that TB non-adherence was associated with low belief in TB curability, low belief in
severity of TB in the presence of HIV infection, and low levels of support from family and
HCWs [12]. Qualitative studies have also cited side effects, pill burden, substance abuse, eco-
nomic constraints, food security, and stigma as risk factors of non-adherence to concurrent TB
treatment and ART [13–16].
While adherence has been studied for TB and HIV individually, factors influencing adher-
ence to concurrent TB treatment and ART in South Africa are less well documented. To our
knowledge, a small number of studies [7, 17–19] have examined concurrent ART and TB treat-
ment in South Africa under programmatic conditions. One study found a high level of adher-
ence [17], while one cross-sectional study found high levels of non-adherence (42.4%) among
patients after 1 month of concurrent treatment [18]. This latter study also found that poverty,
having 1 co-morbid condition, being at risk for alcohol misuse, and having a partner with
HIV were significant factors relating to non-adherence [18]. A qualitative study by Daftary
et al. examined adherence to ART and second-line TB treatment in individuals co-infected
with HIV and MDR-TB or XDR-TB and found that ART was preferred over TB treatment
because of greater tolerability, lower pill burden, and feeling committed to ART [19]. Lastly,
Uyei et al. found that integrated TB and ART service delivery and the delivery of TB and HIV
care by the same clinical team reduced the odds of death [7].
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As the number of TB/HIV co-infected patients increase in South Africa, it is important to
examine factors related to adherence in this population to maximize the effectiveness of both
treatments. Therefore, we conducted a study among persons co-infected with TB/HIV to deter-
mine the level of adherence to concurrent administration of ART and TB treatment and to
identify risk factors for non-adherence in two South African provinces during 2008–2010.
Methods
Setting and Study Population
The study was conducted in two districts of North West Province (NW) (Dr. Ruth S. Mompati
District and Dr. Kenneth Kaunda District) and one district in Western Cape Province (WC)
(Eden District). During the study period, South Africa had the highest TB incidence globally
(997 per 100,000 persons) [20], with incidences of 800 and 965 per 100,000 persons in NW and
WC provinces, respectively [21]. HIV prevalence in South Africa was 10.9%, while prevalence
in NW andWC provinces was 11.3% and 3.8%, respectively [22]. Nationally, HIV co-infection
among TB patients was reported to be 67% [20].
The TB, HIV/AIDS, Treatment Support and Integrated Therapy (THAT’SIT) program was
established in 2006 with the explicit goal of supporting the National Department of Health
(NDoH) in providing a comprehensive range of integrated services for persons with TB and
HIV, including, but not limited to, integrated patient records, implementing community-based
care of TB/HIV co-infected patients, and establishing a community referral network that can
trace patients who did not keep clinic appointments, collection and delivery of patients’medi-
cations, and encouraging HIV and TB screening [23]. A convenience sample of 35 THAT’SIT-
supported NDoH clinics, 23 in NW and 12 in WC, were selected for the study due to financial
and logistic considerations. THAT’SIT maintains an electronic database that serves as the pri-
mary source for TB and HIV patient-level information at the supported clinics [24]. The study
population included all adults (18 years of age) with smear-positive TB (new and retreat-
ment) identified through the THAT’SIT database to be taking concurrent TB treatment and
ART for at least one month during 1 January 2008–30 June 2010. Patients could have already
been on concurrent treatment before the study period. Data collection was censored at 31
December 2010, which meant that the last patient eligible for the study was allowed 6 months
to complete first-line TB treatment (i.e., standard 4-drug regimen). Patients were excluded if
they transferred outside of the study facilities, were documented to have MDR-TB, or were
missing a recorded TB treatment outcome by 31 December 2010.
Study Design and Data Collection
A retrospective chart review of the TB and HIV data sources in THAT’S’IT-supported NDoH
clinics was conducted. These data sources included the South Africa National TB Control Pro-
gramme Blue Card (considered the primary medical chart for TB patients), the government’s
ART wellness form, and THAT’SIT patient forms. The latter were developed to supplement
the government-issued blue card and wellness forms and served as the THAT’S’IT records for
TB/HIV integrated care. We abstracted data on a standardized questionnaire that included
patient socio-demographics, medical treatment history (e.g. pregnancy, chronic diseases, and
mental health), clinical parameters of their current episode of TB disease and HIV, prescribed
TB and HIV treatment regimens and treatment adherence, and the final TB treatment out-
come. Collected data also included WHO clinical stage for HIV, CD4 cell count and viral load
results, ART start and end dates, adverse events, toxicities, substance use, and psychosocial fac-
tors (e.g., disclosure, having a treatment supporter, support group attendance, home visits,
etc.). Trained healthcare workers abstracted and recorded all data at the clinic. Double entry
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data capturing was completed at the South African Medical Research Council regional office in
Pretoria.
Study Definitions
Concurrent treatment was defined as a TB/HIV co-infected patient receiving simultaneous TB
treatment and ART for a minimum of one month. Adherence to concurrent treatment was defined
as taking80% of TB doses by directly observed therapy (DOT, i.e. taking doses daily at the clinic
under supervision of a clinician or at a mutually agreed upon community location under supervi-
sion of a community treatment supporter) as recorded in the TB Blue Card and taking> 90% of
ART doses as documented in the ARTmedical record during the concurrent treatment period.
Adherence percentage cut-offs were determined using previous publications [25–27]. The concur-
rent treatment period occurred at any time during 1 January 2008–31 December 2010. Patients
were defined as non-adherent if they did not meet the criteria for adherence mentioned above.
Analysis
Descriptive statistics were used to describe the demographic, clinical and psychosocial charac-
teristics of all patients included in the study, and by category of adherence (adherent or non-
adherent). The Pearson’s chi square test and the Fisher’s exact test were used for comparisons
by adherence category. To examine factors associated with non-adherence, we examined each
variable individually and calculated risk ratios (RR) and 95% confidence intervals (CI). We
then developed a multivariate model using variables with a P<0.20 on bivariate analysis or
otherwise informed as important through previous studies. Stepwise regression was performed,
and in the final model, factors with a P<0.05 were considered statistically significant. All anal-
yses were conducted using STATA12 (Stata Corp LP, College Station, TX, USA).
Ethical Approval
This study was reviewed and approved by the Institutional Review Boards of the South African
Medical Research Council and the US Centers for Disease Control and Prevention. Ethical
approval was obtained from the two provinces and the respective clinics prior to the study.
This study did not require informed consent because the data was based on existing program-
matic information and retrospectively abstracted from medical charts. Patient records and
information was anonymized and de-identified prior to analysis.
Results
A total of 1,588 TB/HIV patients listed in the THAT’SIT database were identified as potentially
receiving concurrent ART and TB treatment during January 2008–December 2010. Twenty-
two patients were excluded as they were not receiving concurrent ART and TB treatment.
From the remaining 1,566 patients, 314 had missing TB or HIV adherence data and were
excluded from the study, resulting in 1,252 patients included in the final analyses (Fig 1). Over-
all, 11% (n = 138) of patients were not adherent to concurrent treatment. Among these, 55.1%
(n = 76) were adherent to TB treatment only, 35.5% (n = 49) were adherent to ART only, and
9.4% (n = 13) were not adherent to either treatment (Fig 1).
Of the 1,252 persons receiving concurrent TB/HIV treatment, 45.4% were aged 30–39 years,
56.0% (n = 698) were women, and 21.2% (n = 232) were employed (Table 1). Among the 915
persons with measured height and weight, 42% of patients were underweight according to
body mass index. Mental disorder was reported by 6.4% (n = 63) of 985 patients, while more
patients reported substance use (25.6%, 200/782).
Adherence to Concurrent TB Treatment and ART
PLOSONE | DOI:10.1371/journal.pone.0159317 July 21, 2016 4 / 13
The majority of patients (74.4%; n = 928) were classified as a new TB case, and 87.2%
(n = 1092) had pulmonary TB and received either the Category 1 TB regimen (i.e., 2 months of
isoniazid, rifampicin, pyrazinamide, and ethambutol given daily, followed by isoniazid and
rifampicin given daily for 4 months) or Category 2 TB regimen (i.e., 2 months of isoniazid,
rifampicin, pyrazinamide, and ethambutol and streptomycin injections given daily, followed
by IRZE only in the third month, then by IRE during the continuation phase of 5 months)
[28]. The majority of patients received DOT for the full duration of TB treatment (n = 1186,
Fig 1. Study Population Included in TB/HIV Concurrent Treatment Analysis, 2008–2010.
doi:10.1371/journal.pone.0159317.g001
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Table 1. Demographic, clinical, and social characteristics of patients receiving concurrent TB/HIV
treatment in selected THAT’SIT clinics, South Africa, 2008–2010 (N = 1,252). BMI = body mass index;
TB = tuberculosis; IRZE = isoniazid, rifampin, pyrazinamide, ethambutol; DOT = directly observed therapy;
WHO =World Health Organization; HIV = human immunodeficiency virus; ARV = antiretroviral; D4T/3TC/
EFV = stavudine, lamivudine, efavirenz; D4T/3TC/NVP = stavudine, lamivudine, nevirapine.
Characteristic Total
n (%†)





Sex (n = 1247)
Female 698 (56.0)
Male 549 (44.0)
Employment status (n = 1097)
Employed 232 (21.2)
Unemployed 865 (78.9)
BMI at start of concurrent treatment (kg/m2) (n = 915)
Underweight (<18.5) 391 (42.7)
Normal (18.5–24.9) 433 (47.3)
Overweight/Obese (25) 91 (10.0)
Mental disorder (n = 985)
No 922 (93.6)
Yes 63 (6.4)
Substance use (n = 782)
No 582 (74.4)
Yes 200 (25.6)
TB patient category (n = 1247)
New 928 (74.4)
Retreatment 319 (25.6)
TB site of disease
Pulmonary 1092 (87.2)
Extrapulmonary 160 (12.8)
DOT for TB treatment
DOT full treatment course 1186 (94.7)
DOT intensive phase only 26 (2.1)
DOT continuation phase only 39 (3.1)
No DOT 1 (0.1)
WHO clinical HIV stage
Stage 1 72 (7.3)
Stage 2 100 (10.1)
Stage 3 530 (53.6)
Stages 4 287 (29.0)
ARV regimen (n = 1146)
1a (D4T/3TC/EFV) 1072 (93.5)
1b (D4T/3TC/NVP) 74 (6.5)
CD4 at concurrent treatment start, (units) (n = 1011)
200 789 (78.0)
>200 222 (22.0)
Disclosed HIV status‡ (n = 1046)
Yes 1006 (96.2)
(Continued)
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94.7%). Also, 82.6% of patients were at an advanced HIV clinical stage (i.e., WHO clinical HIV
stage 3 or 4) at the onset of concurrent treatment, and 78% had a CD4 cell count<200 cells/
mm3. Lastly, 43.3% of TB/HIV patients experienced one or more toxicities during the first two
months of concurrent treatment (Table 1).
On bivariate analysis, patients with extrapulmonary TB disease had a significantly increased
risk for non-adherence (P = 0.001) (Table 2). Male gender (P = 0.09), unemployment
(P = 0.08), and patients who did not disclose their HIV status to at least one friend or family
member (P = 0.06) were borderline significant (Table 2); all were included in the final multivar-
iate model, however, since P<0.20.
In the final multivariate model adjusted for age, having extrapulmonary TB disease
(RR = 1.71, 95% CI 1.12 to 2.60) and not disclosing HIV status to at least one friend or family
member (RR = 1.96, 95% CI 1.02 to 3.76) remained independent risk factors for non-adherence
to concurrent TB treatment and ART (Table 3). No other variables considered in the multivari-
ate model were significant.
Discussion
Our study found that the majority of patients with TB/HIV were adherent to concurrent treat-
ment at THAT’SIT supported clinics and that patients were more frequently adherent to TB
treatment compared to ART. Factors associated with non-adherence included extrapulmonary
TB disease and not having disclosed HIV status to at least one friend or family member. There
were no significant differences in HIV clinical and treatment characteristics between the adher-
ent and non-adherent groups. More than 80% of the study population were at an advanced
HIV clinical stage and CD4 cell counts were similar between adherent and non-adherent
groups. Such low rates of non-adherence to concurrent treatments suggest that patients may be
able to successfully manage concurrent treatment in resource-limited settings.
Contrary to previous literature [13], HIV disease severity did not play into the factors that
influence adherence in our study, suggesting that other factors might be more important in
adherence.
We found that extrapulmonary TB influenced adherence negatively, which aligns with find-
ings from another study [29]. In the context of HIV, patients with extrapulmonary TB may
have advanced immune suppression, as they are usually sicker patients with advanced HIV dis-
ease, and thus, they are at higher risk for poor treatment outcomes [30]. In the present study,
there were no remarkable differences in WHO stage or CD4 count between patients with TB









†Percentages reflect the proportion among participants with a recorded value for each given variable
(missing were excluded from percent), so totals may not add to 1252.
‡Variable indicates whether or not the patient reported disclosing his or her HIV status to a friend or family
member.
doi:10.1371/journal.pone.0159317.t001
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Table 2. Bivariate relationship between characteristics of persons receiving concurrent TB/HIV treatment in selected THAT’SIT clinics and adher-
ence to treatment (N = 1,252). BMI = body mass index; TB = tuberculosis; HRZE = isoniazid, rifampin, pyrazinamide, ethambutol; HRZES = isoniazid, rifam-
pin, pyrazinamide, ethambutol, streptomycin; DOT = directly observed therapy; WHO =World Health Organization; HIV = human immunodeficiency virus;
ARV = antiretroviral; D4T/3TC/EFV = stavudine, lamivudine, efavirenz; D4T/3TC/NVP = stavudine, lamivudine, nevirapine.
Characteristic Adherent to concurrent ART and TB
treatment, N = 1114 n (%)
Not adherent to concurrent ART and TB





Age at concurrent treatment start, years
<30 212 (86.5) 33 (13.5) ref
30–39 511 (90.0) 57 (10.0) 0.75 (0.50–
1.11)
0.15
40–49 267 (87.8) 37 (12.2) 0.90 (0.58–
1.40)
0.65




Female 630 (90.3) 68 (9.7) ref




Employed 213 (91.8) 19 (8.2) Ref
Unemployed 758 (87.6) 107 (12.4) 1.51 (0.95–
2.41)
0.08
BMI at start of concurrent treatment (kg/m2)
Normal (18.5–24.9) 368 (85.0) 45 (15.0) ref
Underweight (<18.5) 347 (88.7) 44 (11.3) 1.08 (0.73–
1.60)
0.69




No 821 (89.0) 101 (11.0) ref




No 529 (90.9) 53 (9.1) ref




New 826 (89.0) 102 (11.0) ref
Retreatment 283 (88.7) 36 (11.3) 1.03 (0.72–
1.47)
0.89
TB site of disease
Pulmonary 984 (90.1) 108 (9.9) ref
Extrapulmonary 130 (81.3) 30 (18.7) 1.90 (1.31–
2.74)
0.001
DOT for TB treatment
DOT full treatment course 1053 (88.8) 133 (10.2) ref
DOT intensive phase only 22 (84.6) 4 (15.4) 1.37 (0.55–
3.43)
0.50
DOT continuation phase only 38 (97.4) 1 (2.6) 0.23 (0.03–
1.59)
0.14
No DOT 1 (100.0) 0 (0.0) - - - -
WHO HIV stage
Stage 1 65 (90.3) 7 (9.7) ref
(Continued)
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indices changed over the course of treatment. Studies have also shown that patients with extra-
pulmonary TB experience longer treatment delays than patients with pulmonary TB [31]. Fur-
ther research is needed to fully explore the underlying reasons for non-adherence in HIV
patients with extrapulmonary TB.
Our analysis also revealed that non-adherent persons were more likely to have not disclosed
their HIV status to at least one friend or family member. Several studies have found that non-
disclosure is a barrier to retention in care [32–35]. Provision of psychosocial support that
encourages patients to disclose may reduce non-adherence, as patients who disclose their HIV
status to relatives and close friends experience less stigma and discrimination to obtain and
Table 2. (Continued)
Characteristic Adherent to concurrent ART and TB
treatment, N = 1114 n (%)
Not adherent to concurrent ART and TB





Stage 2 91 (91.0) 9 (9.0) 0.93 (0.36–
2.37)
0.87
Stage 3 474 (89.4) 56 (10.6) 1.09 (0.52–
2.29)
0.83




1a (D4T/3TC/EFV) 952 (88.8) 120 (11.2) Ref
1b (D4T/3TC/NVP) 67 (90.5) 7 (9.5) 0.85 (0.41–
1.74)
0.65
CD4 at concurrent treatment start, (units)
200 708 (89.7) 81 (10.3) ref




Yes 899 (89.4) 107 (10.6) ref
No 32 (80.0) 8 (20.0) 1.88 (0.99–
3.58)
0.06
Number of toxicities during the first 2 months
of concurrent treatment
None 631 (88.9) 79 (11.1) ref
1 242 (88.3) 32 (11.7) 1.05 (0.71–
1.54)
0.81




Table 3. Multivariate analysis of the relationship between characteristics of persons receiving con-
current TB/HIV treatment in selected THAT’SIT clinics and non-adherence to concurrent TB and HIV
treatment (N = 1252). TB = tuberculosis, HIV = human immunodeficiency virus.
Characteristic RR (95% CI) P value
Age at concurrent treatment start, years 0.99 (0.97–1.01) 0.34
TB site of disease
Pulmonary ref
Extrapulmonary 1.71 (1.12–2.60) 0.01
Disclosed HIV status
Yes ref
No 1.96 (1.02–3.76) 0.04
doi:10.1371/journal.pone.0159317.t003
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take drugs. In fact, disclosing one’s HIV status was found to be essential for receiving social
support like reminders to take pills, transportation and food costs, and emotional backing [32].
Programs could consider closely monitoring patients who have not disclosed HIV status to a
family member or friend when first initiating ART or TB treatment, or counsel them to dis-
close, as this could be a signal to healthcare providers of the diminished likelihood of adherence
to the complicated regimens for HIV and TB.
Unlike research that shows a preference for ART over TB treatment [19], we found that
patients were more frequently adherent to TB treatment compared to ART. This finding might
be due to the shorter duration that a patient must take TB treatment compared to life-long
ART but may also suggest that the preference for ART may be diminished when patients are
receiving integrated TB/HIV treatment support. With South Africa having a growing burden
of drug-resistant TB, it is important to note that higher adherence to TB treatment as found in
our study may lend credence to programs like THAT'SIT which employed more aggressive
efforts to identify, treat and support TB patients who were found to be HIV positive. THAT'SIT
integrated the empowerment approach of the HIV program by offering patient education,
treatment literacy, adherence counseling and support for effective self-management with the
regular monitoring of the TB program that required routine treatment supervision [23].
Though this study precludes us from drawing direct associations between THAT'SIT and
adherence outcomes, our high co-adherence finding supports evidence that urges review of TB
and HIV treatment provision and the disjuncture between the treatment supervision approach
of the TB program and the patient empowerment design of the HIV program [36].
Historically, HIV and TB have been treated in separate programs and facilities. TB clinics
have been slow to implement HIV care, including the introduction of ART, which has resulted
in the establishment of separate HIV clinics that often do not treat TB co-infection [37–38].
Our findings provide evidence to support integration of TB and HIV services in primary health
care settings as adherence rates in our study are higher than those found in previous studies in
Africa [13,15,16] and consistent with findings of studies with smaller study populations in
KwaZulu-Natal, South Africa receiving integrated care [6, 17].
There were several limitations to our study. First, this was a convenience sample of THAT-
S’IT-supported clinics, and it is possible that these clinics performed differently compared to
other THATS’IT-supported or other integrated TB/HIV clinics; however, we did attempt to
capture both clinics in rural and urban settings. Second, we relied on routinely collected data
for TB and for ART (both standard DoH forms and THAT’S IT databases) for this evaluation,
which was not initially intended for research purposes. We found variability in the ART forms
used across provinces and clinics, which caused difficulty in the standardization of some data
variables. However, while there has been consistent documentation of the inaccuracy of stan-
dard information collected for TB and surveillance purposes [39], previous evaluations have
reported almost perfect levels of completeness and accuracy in THAT’S IT databases, as they
have dedicated staff and utilize supplemental information beyond the standard DoH forms
[24]. Though data were extracted and validated across TB and HIV referencing sources for the
study, data quality and completeness remains a matter of concern in the routine functioning of
public health facilities in South Africa. We were missing adherence information on 314 patients
in the original cohort identified as initiating concurrent treatment during the study period (Fig
1). After performing a sensitivity analysis, it is reasonable that the missing observations are
unlikely to alter the study conclusions because the 314 have similar distributions in their char-
acteristics as the final 1252 included in the study analysis. If a large proportion of these patients
had missing outcomes due to default or noncompliance, however, then our findings would
overestimate adherence to concurrent treatment. Third, the study lacked direct, validated mea-
sures of adherence as confirmed by previous studies [40]. Fourth, factors identified in previous
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literature [41], including adverse events, substance use, and disease severity were not associated
with adherence in this study population, but this may be due to small sample size in the non-
adherent group and missing data. Future research should investigate the impact of patterns of
treatment interruption on adherence. Fifth, this study collected limited data associated with the
social, economic, treatment, and illness-related dimensions of adherence [42] because of data
unavailability; therefore, the study was restricted in its ability to measure the impact that
patient-provider interaction, health system characteristics, and patient-level factors affect
adherence. Lastly, because those patients that were transferred out of the facility were excluded,
and these patients might have poorer adherence, we might have introduced some bias towards
better adherence in this study. While the results of this study apply to THAT'SIT supported
clinics and should only be generalized to other TB/HIV integrated clinics with caution, the
study offers insight to factors that may affect concurrent TB/HIV treatment adherence in simi-
lar high-burden settings.
In conclusion, this study demonstrated the capacity to achieve a high level of adherence to
concurrent TB and ART in an integrated TB/HIV care setting. While the implications of our
findings support the current South African National Strategic Plan to scale-up initiation of
concurrent TB/HIV treatment under integrated care [43], persons with extrapulmonary TB
disease and those who fail to disclose their HIV status to at least one friend or family member
may be at an increased risk for non-adherence to concurrent treatment and should receive
close monitoring to prevent non-adherence. Future studies may further examine underlying
reasons persons fail to disclose their status and the association of extrapulmonary TB disease
and adherence.
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